Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission

Manuel Mendizabal, Federico Piñero, Ezequiel Ridruejo, Margarita Anders, María Dolores Silveyra, Aldo Torre, Pedro Montes, Alvaro Urzúa, Josefina Pages, Luis G Toro, Javier Díaz, Esteban Gonzalez Ballerga, Godolfino Miranda-Zazueta, Mirta Peralta, Isabel Gutiérrez, Douglas Michelato, Maria Grazia Venturelli, Adriana Varón, Emilia Vera-Pozo, Martín Tagle, Matías García, Alfredo Tassara, Julia Brutti, Sandro Ruiz García, Carla Bustios, Nataly Escajadillo, Yuridia Macias, Fátima Higuera-de la Tijera, Andrés J Gómez, Alejandra Dominguez, Mauricio Castillo-Barradas, Fernando Contreras, Aldana Scarpin, Maria Isabel Schinoni, Claudio Toledo, Marcos Girala, Victoria Mainardi, Abel Sanchez, Fernando Bessone, Fernando Rubinstein, Marcelo O Silva, Manuel Mendizabal, Federico Piñero, Ezequiel Ridruejo, Margarita Anders, María Dolores Silveyra, Aldo Torre, Pedro Montes, Alvaro Urzúa, Josefina Pages, Luis G Toro, Javier Díaz, Esteban Gonzalez Ballerga, Godolfino Miranda-Zazueta, Mirta Peralta, Isabel Gutiérrez, Douglas Michelato, Maria Grazia Venturelli, Adriana Varón, Emilia Vera-Pozo, Martín Tagle, Matías García, Alfredo Tassara, Julia Brutti, Sandro Ruiz García, Carla Bustios, Nataly Escajadillo, Yuridia Macias, Fátima Higuera-de la Tijera, Andrés J Gómez, Alejandra Dominguez, Mauricio Castillo-Barradas, Fernando Contreras, Aldana Scarpin, Maria Isabel Schinoni, Claudio Toledo, Marcos Girala, Victoria Mainardi, Abel Sanchez, Fernando Bessone, Fernando Rubinstein, Marcelo O Silva

Abstract

Introduction & objectives: The independent effect of liver biochemistries as a prognostic factor in patients with COVID-19 has not been completely addressed. We aimed to evaluate the prognostic value of abnormal liver tests on admission of hospitalized patients with COVID-19.

Materials & methods: We performed a prospective cohort study including 1611 hospitalized patients with confirmed SARS-CoV-2 infection from April 15, 2020 through July 31, 2020 in 38 different Hospitals from 11 Latin American countries. We registered clinical and laboratory parameters, including liver function tests, on admission and during hospitalization. All patients were followed until discharge or death. We fit multivariable logistic regression models, further post-estimation effect through margins and inverse probability weighting.

Results: Overall, 57.8% of the patients were male with a mean age of 52.3 years, 8.5% had chronic liver disease and 3.4% had cirrhosis. Abnormal liver tests on admission were present on 45.2% (CI 42.7-47.7) of the cohort (n = 726). Overall, 15.1% (CI 13.4-16.9) of patients died (n = 244). Patients with abnormal liver tests on admission presented higher mortality 18.7% (CI 15.9-21.7), compared to those with normal liver biochemistries 12.2% (CI 10.1-14.6); P < .0001). After excluding patients with history of chronic liver disease, abnormal liver tests on admission were independently associated with death [OR 1.5 (CI 1.1-2.0); P = 0.01], and severe COVID-19 (2.6 [2.0-3.3], P < .0001), both adjusted by age, gender, diabetes, pneumonia and body mass index >30.

Conclusions: The presence of abnormal liver tests on admission is independently associated with mortality and severe COVID-19 in hospitalized patients with COVID-19 infection and may be used as surrogate marker of inflammation. CLINICALTRIALS.GOV: NCT04358380.

Keywords: Coronavirus; Death; Hepatitis; Pandemic; SARS-CoV-2.

Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

References

    1. Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:1–12. doi: 10.1136/bmj.m1985.
    1. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. Jama. 2020;323:2052–2059. doi: 10.1001/jama.2020.6775.
    1. Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017–1032. doi: 10.1038/s41591-020-0968-3.
    1. Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526:135–140. doi: 10.1016/j.bbrc.2020.03.044.
    1. Li H., Liu L., Zhang D., Xu J., Dai H., Tang N. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395:1517–1520. doi: 10.1016/S0140-6736(20)30920-X.
    1. Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y. COVID-19: abnormal liver function tests. J Hepatol. 2020;73:566–574. doi: 10.1016/j.jhep.2020.04.006.
    1. Aroniadis O.C., DiMaio C.J., Dixon R.E., Elmunzer B.J., Kolb J.M., Mendelsohn R. Current knowledge and research priorities in the digestive manifestations of COVID-19. Clin Gastroenterol Hepatol. 2020;18:1682–1684. doi: 10.1016/j.cgh.2020.04.039.
    1. Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–678. doi: 10.1016/S2468-1253(20)30126-6.
    1. Phipps M.M., Barraza L.H., LaSota E.D., Sobieszczyk M.E., Pereira M.R., Zheng E.X. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. Hepatology. 2020;72:807–817. doi: 10.1002/hep.31404.
    1. Fan Z., Chen L., Li J., Cheng X., Yang J., Tian C. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18:1561–1566. doi: 10.1016/j.cgh.2020.04.002.
    1. Meszaros M., Meunier L., Morquin D., Klouche K., Fesler P., Malezieux E. Abnormal liver tests in patients hospitalized with Coronavirus disease 2019: should we worry? Liver Int. 2020;40:1860–1864. doi: 10.1111/liv.14557.
    1. Qi X., Liu C., Jiang Z., Gu Y., Zhang G., Shao C. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020;73:455–458. doi: 10.1016/j.jhep.2020.04.010.
    1. Medetalibeyoglu A., Catma Y., Senkal N., Ormeci A., Cavus B., Kose M. The effect of liver test abnormalities on the prognosis of COVID-19. Ann Hepatol. 2020;19:614–621. doi: 10.1016/j.aohep.2020.08.068.
    1. Von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457. doi: 10.1016/S0140-6736(07)61602-X.
    1. Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X. Characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Sarin S.K., Lau G.K., Zheng M.-H., Ji D., Sherief Abd-Elsalam, Hwang J. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum study) Hepatol Int. 2020;14:690–700. doi: 10.21203/-36338/V1.
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. doi: 10.1001/jamacardio.2020.0950.
    1. Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428–430. doi: 10.1016/S2468-1253(20)30057-1.
    1. Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P., Zhu L. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72:389–398. doi: 10.1002/hep.31301.
    1. Bloom P.P., Meyerowitz E.A., Reinus Z., Daidone M., Gustafson J., Kim A.Y. Liver Biochemistries in Hospitalized Patients With COVID‐19. Hepatology. 2020 doi: 10.1002/hep.31326. 0–3.
    1. Fu Y., Zhu R., Bai T., Han P., He Q., Jing M. Clinical features of COVID-19-Infected patients with elevated liver biochemistries: a multicenter, retrospective study. Hepatology. 2020 doi: 10.1002/hep.31446.
    1. Kwo P.Y., Cohen S.M., Lim J.K. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35. doi: 10.1038/ajg.2016.517.
    1. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., Seef L.B. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050–2068. doi: 10.1093/clinchem/46.12.2050.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する